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The problem of distinguishing causes from effects is not a trivial one, as illustrated by
the science ﬁction writer Isaac Asimov in a novel dedicated to an imaginary compound
with surprising “chronochemistry” properties. The problem is particularly important when
trying to establish the etiology of diseases. Here, we discuss how the problem reﬂects on
our understanding of disease using two speciﬁc examples: Alzheimer’s disease (AD) and
Friedreich’s ataxia (FRDA). We show how the ﬁbrillar aggregates observed in AD were
ﬁrst denied any interest, then to assume a central focus, and to ﬁnally recess to be
considered the dead-end point of the aggregation pathway. This current view is that the
soluble aggregates formed along the aggregation pathway rather than the mature amyliod
ﬁber are the causes of disease, Similarly, we illustrate how the identiﬁcation of causes and
and effects have been important in the study of FRDA.This disease has alternatively been
considered as the consequence of oxidative stress, iron precipitation or reduction of iron–
sulfur cluster protein context.We illustrate how new tools have recently been established
which allow us to follow the development of the disease. We hope that this review may
inspire similar studies in other scientiﬁc disciplines.
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INTRODUCTION
THE IMPACT OF DETERMINISM IN OUR LIVES
By philosophical choice or from our simple and most direct per-
ception of reality, we are accustomed to consider the world as
deterministic, i.e., as being ruled and regulated by the principle of
causality. This principle states that each action or event is the con-
sequence of a previous action or event. We cannot have the effect
before the cause. We have plenty of everyday examples: being hit
by a car while crossing a road implies that a car was driving along
the road and run over a person who was crossing the road. Surely
we could not have a car accident before the car’s arrival. Like-
wise, if a cake comes out from the oven this necessarily means
that someone must have baked it and could not be the other way
around.
Occasionally, some dreamers have considered the possibility
that determinism could be violated and explored how this possi-
bility could reﬂect onour life. Aparadigmatic example is that of the
scientist and science ﬁctionwriter IsaacAsimov,whowrote a spoof
of the deterministic concept in a novel dedicated to thiotimoline
(Asimov, 1948). This is supposed to be awonder substance derived
from the bark of the (ﬁctitious) shrub Rosacea karlsbadensis rufo.
Thiotimoline has the property of solubilising exactly 1.2 s (not
a second before or after) before the researcher adds water to the
compound, thus challenging the principle of cause and effect as in
this case the effect would precede the cause. . . The author’s expla-
nation for such extraordinary behavior is chemically “rigorous”
although highly ﬁctional: in the thiotimoline molecule, there is at
least one carbon atom that has two of the four chemical bonds in
the normal space and time dimensions; one of the other two bonds
projects into the future and the other into the past, thus bridging
time. As imagined by Asimov, if true, the consequences would
be unimaginable: the substance could be used to create fantastic
mechanisms that could be exploited in “chronochemistry,” a dis-
cipline of Asimov’s invention which only Russian scientists excel
in while the Americans, more suspicious, are unfortunately left
behind. . .
Letting aside this and similar ﬁctional possibilities, the con-
cepts of determinism and causality remain simple and undeniable
certainties that rule our everyday lives.
Where things go fuzzier is when we do not know the events
that well. Not that we would doubt their deterministic nature
but there might be cases in which it is difﬁcult to distinguish
between cause and effect. The concept acquires a dramatic impor-
tance when referred to medicine, a ﬁeld where the problem of
identifying the correct causality is directly related to diagnostics.
Failure to identify the cause, or confusion between cause and effect,
can direct the cure along false paths making it ineffective, if not
dangerous. A heavy headache and stomach sickness could well
be explained by assuming that having developing a headache we
started also having an upset stomach. But it is equally possible
that because of feeling sick we developed headache or even that
the two events are uncorrelated and that the two pathological
conditions came out at the same time, perhaps as the effect of
a third event such as a viral attack or any other direct or indirect
cause.
There are in principle three criteria that need to be met before
we can say that there is a causal relationship between two events.
First, we must be able to show that there is a temporal sequence
of events and that the cause happened before the effect. Second,
there should be co-variations of the cause and the effect: if one
parameter inﬂuencing one event was increased, the other event
should be affected in a simple binary relationship. Finally, it should
be possible to rule out plausible alternative explanations that could
explain the co-detection of the two events. Most often, establishing
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these three criteria is far from being easy, especially when we wish
to apply them to biology or medicine.
In this review, we discuss the difﬁculties of identifying cause
and effects in speciﬁc biological events that are directly related
to neurodegeneration and the problem of identifying disease
etiology. We show how the problem can be clariﬁed by the possi-
bility of identifying a clear “time zero” (i.e., the time point when
the chain of events causing the disease starts) and by checking
how the symptoms accumulate from this point. We shall con-
sider two paradigmatic examples: the case of the amyloid-related
Alzheimer’s disease (AD) and the example of Friedreich’s ataxia
(FRDA), two diseases studied widely in the last few years. We shall
also discuss the implications that these speciﬁc examples have for
our understanding of the biological phenomena causing disease.
THE PROBLEM OF ESTABLISHING CAUSES AND EFFECTS IN DISEASE
ETIOLOGY
Alzheimer’s disease is an aging-related disease of increasing impact
for the world population which involves impairment of memory,
reasoning, abstraction, and language (Christensen et al., 2009).
The cytological and biochemical complexity of this disease has
made it difﬁcult to ﬁnd an easy agreement on the temporal
sequence of events that lead to AD and, as a consequence, on the
steps most amenable to drug treatment. AD was ﬁrst diagnosed
and studied by the Bavarian psychiatrist Alois Alzheimer, who
identiﬁed the presence of unusual formations in the post-mortem
brain of a 51 year old patient (Alzheimer, 1907). These lesions
are known as amyloid plaques as amyloid plaques and neuroﬁb-
rillar tangles according to their morphology and location (Selkoe,
2011; Serrano-Pozo et al., 2011). Only much later, it became clear
that the lesions are proteinaceous formations that mainly con-
tain, respectively, Aβ peptides that are degradation products of the
“amyloid precursor protein” (or APP) (Kang et al., 1987) and the
microtubule-associated protein (MAP) tau protein (Brion et al.,
1985; Masters and Selkoe, 2012).
We now know that these two molecules are intrinsically
unstructured polypeptides that are highly hydrophobic and have
a high tendency to misfold and form ﬁbrillar aggregates termed
amyloids from their tintorial properties. It is accepted that amyloid
ﬁbers adopt a β-rich structure of the same type as that observed
in silk (Marshall and Serpell, 2009). The conversion of α-helix or
random coil conformations within normally soluble proteins into
β-sheet rich assemblies is a common theme recurrent in several
neurodegenerative diseases and has been shown to be a univer-
sal solution of the energy landscape common to most if not all
proteins (Eichner and Radford, 2011; Ma and Nussinov, 2012).
Interestingly, the presence of plaques and tangles was inter-
preted differently through time. When Glenner and Wong (1984)
ﬁrst identiﬁedAβ frompost-mortemmeninges of ADpatients, the
authors suggested that these formations could “provide a diagnos-
tic test for AD and a means to understand its pathogenesis.”Other
scientists argued instead that the plaques and tangles might “only”
be end-stage lesions and that would provide little useful informa-
tion about etiology and early pathogenesis. Nevertheless, plaques
and tangles have been used as diagnostic tools for several decades.
As a consequence many people adopted what is known as the
“amyloid hypothesis,”which assumes that extracellular deposits of
Aβ peptides are the fundamental cause of AD (Hardy and Allsop,
1991; Mudher and Lovestone, 2002; Luheshi et al., 2008). Inspired
by these studies, amyloid ﬁbers have been thoroughly studied and
large attention has been paid to them not only in the AD ﬁeld but
in several other, otherwise uncorrelated diseases also associated to
protein aggregates (Luheshi et al., 2008).
Association does not however, necessarily imply a causal rela-
tionship even though this inference is rather tempting. More
recently, it has become progressively clear that AD could not after
all be caused by the ﬁnal mature amyloid ﬁbers but by other
species which form along the aggregation pathway. It has been
suggested that the formation of amyloid ﬁbers could even be a
defense mechanism of the cell to protect itself from other more
toxic species which have recently been identiﬁed in the so called
oligomers (Hardy and Selkoe, 2002). These are assembly species
formed along the aggregation pathway but well before the mature
ﬁbers are formed. The importance of the oligomers rather than
mature ﬁbers is supported by several lines of evidence.
Some patients develop severe symptoms well before plaques are
formed or at least are detectable. Conversely, plaques can be found
in the cortex of aged subjects who are at least apparently healthy,
although it is possible that theymight have not been tested for sub-
tle cognitive dysfunctions. Oligomers, that is all forms that remain
soluble after high-speed ultracentrifugation of brain extracts and
not of ﬁbrillar forms, are detectable in buffer-soluble extracts of
post-mortem AD patients’ cortex (Shankar et al., 2008). These
species are cytotoxic as shown for the ﬁrst time by Lambert et al.
(1998). Later on, injection of oligomeric (dimers) species into the
cerebral ventricles of healthy adult rats conﬁrmed that they tran-
siently impair the memory of a learned behavior (Shankar et al.,
2008). Aβ oligomers have been shown to cause neuronal death
in culture and to block long-term synaptic depression (Lambert
et al., 1998; Stine et al., 2003; Wang et al., 2004). There is a sta-
tistical correlation between cortical levels of soluble Aβ and the
extent of synaptic loss and severity of cognitive symptoms (Kuo
et al., 1996; Lue et al., 1999; McLean et al., 1999; Wang et al., 1999).
Oligomers of the size of Aβ dimers but not monomeric species
from the same brains were shown to facilitate long-term synaptic
depression in the hippocampus and to decrease dendritic spine
density (Shankar et al., 2008; Li et al., 2009b).
Taken together, these ﬁndings support the hypothesis that
small, soluble oligomers of human Aβ peptides are sufﬁcient to
induce several features of the AD phenotype, including synap-
tic loss, tau hyper-phosphorylation, neuroﬁbrillary degeneration,
and memory impairment, even in the absence of amyloid plaques.
When we determine the presence of plaques, in fact, most of the
damages have already taken place. Thus the ﬁbrillar aggregates
could be the ultimate effect, the escape and not the cause of AD
(Figure 1).
The lesson we may learn from this story could be a hard one.
It could be argued that confusion between cause and effect has
been negative and has distracted researchers from the “real thing,”
encouraging them to follow the wrong pathway. At least 10 years
have been dedicated to a thorough study of the morphologi-
cal, mechanical and structural properties of amyloids. However,
we can convincingly argue back that it has not been a waste of
time in the broader perspective of our fundamental knowledge
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FIGURE 1 | Debated role of fibrillar amyloids. A recurrent question
which seems to become clear only recently is whether the ﬁbrillar amyloid
species observed in patients’ brains are the toxic species or rather a
defense mechanism of the cell. The current view is that the toxic species
are the soluble aggregates formed through the aggregation process. As
such, the mature ﬁbrillar ﬁbres are the ﬁnal point of this process.
of reality. It is now clear that amyloids are not “just” a rare or
totally unwanted structure. Amyloid peptides are routinely found
in hormones (Maji et al., 2009) and are produced by E. coli and
other gram-negative enteric bacteria (Wang et al., 2008) and by
the gram-positive bacterium S. coelicolor (Capstick et al., 2011).
While some of the interest in amyloid ﬁbers could be considered
ineffective and dangerously delaying an anti-Alzheimer treatment,
our “detour” into the amyloid world will certainly prove highly
beneﬁcial for many other areas of Biology in the close future.
THE IMPORTANCE OF DETECTING THE VERY EARLY EVENTS OF
A DISEASE
Let’s now consider the example of FRDA. This is a neurodegen-
erative disease caused by an abnormal expansion of a non-coding
GAA triplet repeat in the ﬁrst intron of the FRDA gene (Pas-
tore and Puccio, 2013). This event causes lower expression of
the FRDA gene product, the protein frataxin, through hetero-
chromatization of the locus. The age of disease onset correlates
inversely with the number of repeats. FRDA provides a unique
example (of still ongoing research) in which causes and effects can
easily be mixed up until the “‘right” experiments are designed to
establish a temporal relationship between observations.
A large body of work has been produced since the discovery
of the gene responsible for this ataxia (Campuzano et al., 1996).
We now know that frataxin is a nuclearly encoded protein, pro-
duced in the cytoplasm and then imported into andmatured in the
mitochondrion where its primary function resides. To reach this
conclusion it was noticed early on that only eukaryotic frataxins
contained an N-terminal extension that could represent an import
signal (Gibson et al., 1996). It was also noticed that the distribution
of the frataxin gene in different organisms is fully consistent with
the fusion event that leads to the formation of mitochondria. The
hypothesis was soon after independently proven experimentally
(Campuzano et al., 1997).
But what is the role of frataxin in mitochondria? One of the
early observations was that of iron deposits in heart tissues of
FRDA patients (Sanchez-Casis et al., 1977). This was conﬁrmed
by a deletion mutant in yeast (YFH1) that showed a ten-fold
increase in the iron concentration inmitochondria and an increase
of hypersensitivity to oxidative stress (Babcock et al., 1997). A
more complete investigation of the molecular defects present in
patients carried out by Rustin and his group identiﬁed a deﬁ-
cient activity of iron–sulfur (FeS) cluster-containing subunits of
mitochondrial respiratory complexes I, II, III and aconitase in
endomyocardial biopsies (Roting et al., 1997). The authors made
an attempt to create a temporal connection between the observed
strong and yet very different phenotypes. They concluded that
iron overload is the “causa prima” that generates oxidative stress
through iron-catalyzed Fenton chemistry. This would in turn give
rise to oxygen free radicals and iron precipitates. The latter are well
known to target efﬁciently FeS proteins causing them to quickly
lose their activities as observed in patients and yeast-null mutants
generating the pathology. The authors did not, however, provide
any indication of where iron could come to the equation which
left the explanation somewhat unsatisfactory.
To address the question in a different way, several laborato-
ries developed animal and cellular models that could allow the
study of the multiple effects generated by the reduced production
of frataxin as observed in disease. These studies rely on the high
conservation of the frataxin gene along evolution, which makes
possible to model the effects of frataxin deletion in different sys-
tems and compare the effects to those observed in patients’ cells. A
homozygous mouse model in which the frataxin gene was drasti-
cally switched off was the ﬁrst attempt to understand the primary
events caused by the absence of the protein and the cellular phe-
notype of FRDA (Cossée et al., 2000). This homozygous deletion
caused embryonic lethality a few days after implantation, indicat-
ing that frataxin is an essential protein in mammals. Surprisingly,
though, no iron overload or iron precipitates were detected in
degenerating embryos, in open contrast with the hypothesis that
iron precipitates are the primary cause of the pathology, thus sug-
gesting that they could be instead a side-effect. These ﬁndings were
explained assuming that yeast frataxin could have a ferritin-like
function as an iron storage chaperone within the mitochondria
(Isaya et al., 2000). Cell death in mouse embryos would be the
consequence of the lack of a scavenger rather than the result of
iron precipitation, reinforcing the idea that iron deposits are a
secondary event.
It is important however, to consider that the discrepancy
between the data in yeast, in patients and in transgenic mice could
be more simply explained by the unfair comparison of condi-
tions detected at very different time points of the disease course.
Iron precipitation is the most striking phenomenon observed in
patients’ tissues, where the disease is usually present for years, and
in yeast-null mutants grown for many generations before been
used in experiments. In embryos instead, iron accumulation could
hardly have time to build up, thus giving a better description of
what the cause and the effects may be. Embryos could in facts be
an ideal system to capture the early events close to what we shall
call “time zero,” that is the disease onset.
To better understand the time relationship between events, dif-
ferent laboratories developed conditional knock-out mice for the
frataxin gene (Puccio et al., 2001; Martelli et al., 2012) or yeast
models in which the gene was put under a galactose-regulated
promoter in yeast (Muhlenkhoff et al., 2002). Both systems would
allow switching off the gene at a given time point so that this could
be taken as “time zero” from which the effects could be followed
with controlled molecular and functional assays. To obtain the
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same effect inDrosophila, an RNAi-mediated-suppression strategy
was used (Anderson et al., 2005; Llorens et al., 2007). These mod-
els all revealed that frataxin deﬁciency primarily leads to strong
defects in FeS cluster containing proteins and FeS cluster matura-
tion followed by accumulation of iron deposits. In yeast, a defect in
respiratory efﬁciency was also detected (Muhlenkhoff et al., 2002),
following the disruption of FeS cluster maturation. In mouse, the
FeS cluster deﬁcit is observed before the ﬁrst evidence of a cardiac
dysfunction (Martelli et al., 2012). Interestingly, no evidence of
oxidative damage was observed in this and in a Drosophila model
(Anderson et al., 2005; Llorens et al., 2007). This observation led
to the still open question of whether formation of oxygen free
radicals (ROS) is at all essential to generate the cellular phenotype
associated with FRDA.
The experiments described above were excellent attempts to
generate animal models in which frataxin production could be
controlled and lowered “to induce the disease,” starting the obser-
vation of the molecular and cellular phenotype at a well-deﬁned
time. However, although conceptually correct, such studies were
often carried outwithout any attempt to investigate the actual time
course of events: the phenotype was tested only at few time points
which were often spaced different weeks apart. Unfortunately, as
inAD,when the phenotype becomes observablemost of the events
that lead to it have already taken place.
A more direct approach became possible when the proteins
associated with the FeS cluster biogenesis machine were puri-
ﬁed, both in eukaryotes and prokaryotes (Adinolﬁ et al., 2009;
Prischi et al., 2010). This allowed the possibility of reproducing
the FeS cluster biogenesis machine in vitro and of studying the
effect of frataxin on the formation of de novo synthesized FeS clus-
ters without the complexity of the in vivo/in cell environments.
What makes these experiments particularly attractive is also that
the time course of the events can be followed directly and in a
continuous way. Data are now available for the bacterial (Adinolﬁ
et al., 2009; Prischi et al., 2010), yeast (Li et al., 2009a), and human
(Tsai and Barondeau, 2010; Bridwell-Rabb et al., 2012) systems
and have provided a great deal of new information. These studies
clearly showed that frataxin and its orthologs play a critical role
in regulating FeS biogenesis. These ﬁndings were rationalized by
the report that frataxin and its orthologues bind speciﬁcally and
stoichiometrically to the complex Nfs1/Isu (or IscS/IscU in bacte-
ria; Tsai and Barondeau, 2010). These proteins are the two central
components of the FeS cluster assembly machine, being respec-
tively the desulphurase that provides sulfur for cluster assembly
and the scaffold protein on which the cluster forms.
Much as this approach clariﬁed some issues, it could however,
be noticed that the in vivo and in vitro experiments so far described
have a completely different time frame for the appearance of the
effect of frataxin deﬁciency letting uswonderwhether or how these
results can really be compared to each other and reconciled.
To ﬁll the gap and be able to observe and quantify the effects
of frataxin in a time frame as close as possible to the in vitro stud-
ies, Tamarit and co-workers have recently suggested an alternative
approach: they developed a yeast model placing frataxin under a
controlled promoter (Moreno-Cermeno et al., 2010). The authors
used tetO-YFH1 mutants where the addition of doxycycline to
the growth medium allows an efﬁcient and speciﬁc repression of
frataxin expression. This drug is known not to affect other gene
expression. The system was used to follow the effects of frataxin
deletion in vivo, starting the measurements of different param-
eters at the time of addition of doxycycline, and following the
time evolution using time-points close to the in vitro experiments
(Moreno-Cermeno et al., 2010). Tamarit and co-workers’ results
indicate that the deregulation of iron metabolism is the primary
effect of frataxin depletion, followed by iron accumulation (visible
after 4 h) that occurs at the early stages. They also demonstrated
that increased oxidative damage and decreased concentration of
FeS cluster proteins such as aconitase, are late defects visible only
after 24 h, and might be considered as secondary effects that
are a consequence of iron overload. A possible criticism of this
study could be that the residual activity of the FeS cluster proteins
after frataxin depletion could be explained by a longer half-life of
these proteins. This possibility can be ruled out, since reduction of
expression of proteins responsible for FeS cluster biogenesis leads
to a more than 80% reduction of aconitase activity (Rodriguez-
Manzaneque et al., 2002; Kumanovics et al., 2008). The presence of
normal aconitase activity for 24 h after frataxin depletion cannot
thus be attributed to the initial holo-aconitase pool, but indicates
that the FeS cluster machine remains active even in the absence of
frataxin.
While more work is still needed to clarify several aspects, the
approach proposed by Tamarit together with the in vitro studies
provide powerful tools to clarify the temporal pipeline of FRDA
and hold a tangible promise for understanding the cellular role of
frataxin and its connection to disease (Figure 2).
CONCLUSION
In this review we have discussed the difﬁculties of understanding
disease etiology, a problem that, if anything, is becoming even
FIGURE 2 | Understanding the time course of the events triggered in
disease. The debate is whether iron accumulation is the cause or just an
effect of iron–sulfur (FeS) cluster deregulation and/or of the oxidative stress
and of course which of the two comes ﬁrst as in the chicken and egg
causality dilemma.
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more important in our molecular medicine era. The problem
is of particular interest in neuroscience where many diseases are
poorly understood and interconnected with several different and
apparently uncorrelated symptoms. We discussed two examples
in which causes and effects have been confused, AD and the less
well known FRDA. The former exempliﬁes well how the same
symptomatology can be considered the aetiological cause or even
a defense mechanism which, rather than harming the organism, is
activated to prevent further damages. The same concept has been
transferred to other neurodegenerative diseases which share with
AD the presence of protein aggregates. FRDA provides a unique
example of how experiments can and must be tailored to clarify
the time sequence of events. Although still ongoing, the research
in this ﬁeld has made enormous progresses from its early days and
holds the promise of unveiling soon the exact mechanism of this
still incurable disease.
The take home message that this discussion suggests is that
much care needs to be taken before jumping to conclusions and
assuming that all factors associatedwith a disease are its very cause.
At the same time, we propose the importance of designing suitable
experiments that may clarify the temporal relationship between
events as the only way to understand the mechanisms responsible
for disease onset.
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